Figure 1.

Cohort characteristics and blinatumomab response. (A) CONSORT diagram of B-ALL patients included in the study. (B) Ribbon plot showing response to blinatumomab in each genomic subtype. Patients with full hematological disease (≥5% blasts; 42 of 44 patients) were included for response analysis. (C) Genomic alterations identified by whole-genome sequencing and whole-exome sequencing (WES) in blinatumomab responders compared with nonresponders (NRs). del, deletion; dim, diminished; ins, insertion; neg, negative; Ph, Philadelphia chromosome; pos, positive.